Cholinergic Innervation and Muscarinic Receptors in the Human Prostate

Slides:



Advertisements
Similar presentations
Medical Management for BPH: The Role of Combination Therapy
Advertisements

The PSA Era is not Over for Prostate Cancer
Volume 43, Issue 5, Pages (May 2003)
Volume 60, Issue 2, Pages (August 2011)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Volume 57, Issue 3, Pages e22-e23 (March 2010)
Volume 54, Issue 4, Pages (October 2008)
Control of Prostate Cancer by Transrectal HIFU in 227 Patients
Volume 71, Issue 4, Pages (April 2017)
Seminal Vesicle Invasion by Adenocarcinoma of the Prostate
Volume 54, Issue 4, Pages (October 2008)
Volume 71, Issue 6, Pages e171-e172 (June 2017)
Let the Games Begin (with EAU Approval)
Prostate Cancer Epidemic in Sight?
Volume 43, Issue 5, Pages (May 2003)
Volume 63, Issue 4, Pages e53-e56 (April 2013)
Martin C. Michel  European Urology Supplements 
Bladder Cancer: A Major Public Health Issue
The Global Risk of Bladder Cancer: Let's Just Do Something About It!
Volume 46, Issue 4, Pages (October 2004)
The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.
Back to the Future: Introduction and Conclusions
Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey  John B. McKinlay, Carol L. Link  European.
Volume 54, Issue 4, Pages (October 2008)
Alexandre de la Taille  European Urology Supplements 
Pseudohyperplastic Adenocarcinoma of the Prostate
Volume 51, Issue 1, Pages (January 2007)
Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka 
Volume 70, Issue 3, Pages (September 2016)
Low-risk Prostate Cancer: Identification, Management, and Outcomes
Volume 64, Issue 4, Pages (October 2013)
Volume 60, Issue 1, Pages (July 2011)
Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?
Volume 60, Issue 4, Pages (October 2011)
Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening?  Bob Djavan  European.
Volume 72, Issue 3, Pages (September 2017)
International Society of Urological Pathology Grading and Other Prognostic Factors for Renal Neoplasia  Brett Delahunt, John R. Srigley, Lars Egevad,
Volume 52, Issue 4, Pages (October 2007)
Prostate Cancer Epidemic in Sight?
The PSA Era is not Over for Prostate Cancer
Volume 70, Issue 1, Pages e27-e28 (July 2016)
The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer
Re: Yves Allorya, Willemien Beukers, Ana Sagrera, et al
Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia
Richard C. Harkaway  European Urology Supplements 
Volume 47, Issue 1, Pages (January 2005)
Volume 54, Issue 2, Pages (August 2008)
Training in Percutaneous Nephrolithotomy—A Critical Review
The Economic Costs of Overactive Bladder in Germany
Volume 50, Issue 5, Pages (November 2006)
Volume 53, Issue 6, Pages (June 2008)
CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System
Volume 55, Issue 3, Pages (March 2009)
Tim Schneider  European Urology Supplements 
Volume 54, Issue 4, Pages (October 2008)
How and When to Take Prostate Biopsies
Sergio Bracarda  European Urology Supplements 
Jean J.M.C.H. de la Rosette, Vladimir Mouraviev, Thomas J. Polascik 
What are the Data on 5α-Reductase Inhibitor Treatment of Benign Prostatic Hyperplasia from Everyday Practice?  François Desgrandchamps  European Urology.
European Urology is “Your” Journal
The Start-Up of the Platinum Journal: A Fascinating Challenge
Martin Michel, Jean de la Rosette  European Urology Supplements 
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Prognostic Factors in Non–Muscle-Invasive Bladder Tumors
Annika Berntsen, Poul F. Geertsen, Inge Marie Svane  European Urology 
Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas 
Volume 54, Issue 1, Pages (July 2008)
Volume 51, Issue 5, Pages (May 2007)
Michael Marberger  European Urology Supplements 
Vassilios Tzortzis, Stavros Gravas, Jean J.M.C.H. de la Rosette 
Presentation transcript:

Cholinergic Innervation and Muscarinic Receptors in the Human Prostate Lambertus P.W. Witte, Christopher R. Chapple, Jean J.M.C.H. de la Rosette, Martin C. Michel  European Urology  Volume 54, Issue 2, Pages 326-334 (August 2008) DOI: 10.1016/j.eururo.2007.12.007 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 Schematic diagram of cholinergic nerves and muscarinic receptors in the human prostate. Note that M2 receptors on stromal smooth muscle cells quantitatively play a smaller role than M1 receptors on epithelial cells or α1A-adrenoceptors on smooth muscle cells and that signal transduction and smooth muscle and epithelial cell function presently have been tested in few studies only (see text for details). European Urology 2008 54, 326-334DOI: (10.1016/j.eururo.2007.12.007) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 Presence of muscarinic receptors as compared to α1- and α2-adrenoceptors in the human prostate. Receptor expression was studied in two groups of men, referred to as “asymptomatic benign prostatic hyperplasia” and “symptomatic benign prostatic hyperplasia” by the original authors, with the former actually representing patients with invasive transitional cell carcinoma; the average prostate weight of the two groups is shown in parentheses. Note that the relative proportions of muscarinic receptors and α1- and α2-adrenoceptors were similar in both groups. Adapted from Gup et al. J Urol 1990;143:179–85. European Urology 2008 54, 326-334DOI: (10.1016/j.eururo.2007.12.007) Copyright © 2008 European Association of Urology Terms and Conditions